Deborah Wexler discusses the findings from GRADE, a head-to-head study comparing glimepiride, sitagliptin, insulin glargine, and liraglutide when used in combination with metformin for the treatment of type 2 diabetes.
ADA 2021 interviews
27-06-2021 | ADA 2021 | Conference coverage | Video
Francesco Giorgino discusses the advantages of tirzepatide over insulin degludec revealed in the SURPASS-3 findings for people requiring an injectable therapy for type 2 diabetes.
28-06-2021 | ADA 2021 | Conference coverage | Video
Juan Pablo Frías explains the significance of the SURPASS-2 findings, in which the dual agonist tirzepatide provided superior glycemic control and weight loss to semaglutide.
28-06-2021 | ADA 2021 | Conference coverage | Video
Juan Pablo Frías discusses whether the findings of SUSTAIN-FORTE will justify an increase in the approved maximum dose of semaglutide for people with type 2 diabetes.
29-06-2021 | ADA 2021 | Conference coverage | Video
Findings from the GRADE study, a head-to-head comparison of four commonly used diabetes drugs given together with metformin, suggest that liraglutide and insulin may result in better glycemic control than glimepiride and sitagliptin among people with type 2 diabetes.
29-06-2021 | ADA 2021 | Conference coverage | Video
Deborah Wexler discusses the findings from GRADE, a head-to-head study comparing glimepiride, sitagliptin, insulin glargine, and liraglutide when used in combination with metformin for the treatment of type 2 diabetes.
29-06-2021 | ADA 2021 | Conference coverage | Video
Patrick Holmes discusses whether the GRADE study answers the question of which type 2 diabetes medication should be used after metformin, and comments on the generalizability of the findings.
ADA 2021 research news
07-07-2021 | ADA 2021 | Conference coverage | News
